"十四五"以来福建科技创新成果丰硕 来源：中国新闻网 编辑：张嘉怡 广告等商务合作，请点击这里 不仅如此，福建坚持夯实企业科技创新主体地位，推动企业主导产学研融通创新，助力发展新质生产 力。 李志忠说，福建实施高新技术企业"增量提质"计划和规上工业企业"全覆盖两提升"行动，国家高新技术 企业数量从2020年至2025年，年均增长24%。全省培育371家国家级专精特新"小巨人"企业和54家国家 级制造业单项冠军企业，着力打造高质量创新型企业矩阵。 同时，福建完善企业研发投入财政奖补政策，"十四五"以来累计为11433家次企业提供42.5亿元的研发 投入分段补助；约有6.8万家次企业享受研发费用税前加计扣除3100亿元。 据悉，福建省拥有4个万亿级产业集群、20个超千亿产业集群，以及16个国家级和60个省级中小企业特 色产业集群。2024年全省数字经济规模达到3.2万亿元，占地区生产总值的比重超过55%。(完) 中新网福州10月23日电 (郑江洛)23日，福建省科技厅党组书记、厅长李志忠于福州召开的新闻发布会上 表示，五年来，福建全省科技系统实施创新驱动发展战略，深化科技体制改革，优化科研攻关布局，强 化山海协作 ...

这5年，厦门全力构建"4+4+6"现代化产业体系，三次产业结构优化为0.3:36.6:63.1。数字经济规模超 5000亿元，海洋生产总值占全市GDP达30%，电子信息、机械装备等4大支柱产业集群规模超2.1万亿 元，高技术制造业增加值占规上工业增加值比重达到39.7%。海辰储能、瑞幸咖啡已成长为全球独角 兽，"十四五"期间新培育出生物医药、新能源、新材料等3个千亿元产业链群。 10月21日，福建省厦门市政府新闻办举办"厦门这五年"系列主题新闻发布会首场发布会，介绍"十四 五"时期厦门全面深化改革开放、全方位推动高质量发展的成就情况。 厦门是一座为改革开放而生、因改革开放而兴、凭改革开放而强的城市。5年来，厦门始终牢记嘱托， 完整准确全面贯彻新发展理念，制定实施了《厦门"一二三"战略规划》，推动"十四五"规划高质量完 成。 面对复杂严峻的外部环境和多重困难考验，厦门经济展现出强大韧性，2020年至2024年，地区生产总值 从6384亿元增加到8589亿元，连续跨越两个千亿大关，人均GDP从12.4万元增加到16万元。厦门以全省 1.4%的土地面积，创造出全省14.9%的GDP、26.8%的财政收入、46.9% ...

这5年，厦门聚力强化企业创新主体地位，着力承接全国高校和科研院所技术转移转化，促进更多科技 成果由样品变成产品、形成产业。实施1775项企业高新技术成果转化项目，碱性电解水制氢、高性能浮 力材料等近百项产品或技术达全国乃至全球领先水平；今年6月国内首支九价宫颈癌疫苗获批上市，打 破国外产品十几年的市场垄断。仅今年前三季度就新增2个一类创新药获批上市。 此外，厦门大力深化体制机制改革，持续推动创新链、产业链、资金链、人才链"四链融合"，全社会各 类创新主体的活力和动力竞相迸发。5年来，厦门率先成立市委教育科技人才工作领导小组，深化教育 科技人才一体发展；颁布实施《厦门经济特区促进科技创新若干规定》等一批地方性法规；近3年每年 都出台实施科技创新引领工程系列重磅政策措施，系统改革科技管理、科技投入、人才引育模式，有力 保障城市科技创新与产业创新一体推进、融合发展。同时动态升级"财政政策+金融工具"科技创新和产 业转型升级支持体系，整合设立总规模50亿元科创风投基金，新设科创增信子基金，市技术创新基金规 模扩大到500亿元，创新推出"厦研保"科技保险产品，助力企业创新发展。 厦门是一座拥有"开放基因"的城市。"十四 ...

Company Overview - Wante Bio (603392) closed at 54.66 yuan as of August 15, 2025, down 3.0% from last week's 56.35 yuan [1] - The stock reached a high of 57.1 yuan and a low of 54.24 yuan during the week, hitting its lowest point in nearly a year [1] - The current market capitalization is 69.152 billion yuan, ranking 1st in the bioproducts sector and 223rd among all A-shares [1] Recent Developments - Wante Bio announced the use of 550 million yuan of idle raised funds for cash management, approved by the sixth board and supervisory meetings [1] - The maximum amount for investment in principal-protected products is capped at 1.5 billion yuan, with individual product terms not exceeding 12 months [1] - The total raised funds amount to approximately 3.5 billion yuan, with net proceeds of about 3.46 billion yuan after deducting issuance costs [1] Investment Products - The company is investing in structured deposits, specifically "Juyin Exchange Rate - Linked to Euro to US Dollar Exchange Rate Interval Accumulated Structured Deposit" and "Juyin Exchange Rate - Linked to Euro to US Dollar Call Three-Element Structured Deposit" [1] - The investments are allocated as 200 million yuan and 350 million yuan respectively, with both products having a term of 364 days [1] - Expected annualized returns for these products range from 1.20% to 2.03% [1]

Core Viewpoint - Wantaibio (603392.SH) is facing its first loss since its listing, with a projected net profit loss of between 130 million to 160 million yuan for the first half of 2025, following a significant decline in performance since 2022 [3][4]. Financial Performance Summary - In 2022, Wantaibio achieved a peak revenue of 11.185 billion yuan and a net profit of 4.736 billion yuan, primarily driven by its vaccine products [4]. - The company's revenue dropped by 50.73% in 2023, with a net profit decline of 73.65%, and continued to decrease in 2024, with revenues of 5.511 billion yuan and 2.245 billion yuan, and net profits of 1.248 billion yuan and 106 million yuan respectively [3][4]. - In Q1 2025, Wantaibio reported a loss of 52.7769 million yuan, indicating a significant downturn in financial health [4]. Product Dependency and Market Challenges - The decline in Wantaibio's performance is attributed to its heavy reliance on a single product, the bivalent HPV vaccine, which has seen a drop in sales following the introduction of competing products from Merck [3][6]. - The company increased its production and inventory of the bivalent vaccine in 2022, but faced a 41.94% drop in sales volume in 2023, while inventory levels rose by 91.62% [8]. New Product Launch - Wantaibio has launched a new nine-valent HPV vaccine, "Xinkening 9," priced at 499 yuan per dose, significantly lower than Merck's offering at 1320 yuan [9]. - Despite the competitive pricing, the late entry into the market poses challenges, as Merck's nine-valent vaccine has already established a foothold, and other domestic competitors are also advancing in this space [9][10].